Increased Ferritin with Contraceptives Containing Ethinyl Estradiol Drospirenone in Polycystic Ovary Syndrome: a Paradox of Iron Storage and Iron Deficiency

Overview

Journal Endocrine

Specialty Endocrinology

Date 2024 Dec 31

PMID 39738891

Authors

Naile Gokkaya

Gizem Gecmez

Serhat Ozcelik

Mithat Biyikli

Kadriye Aydin

Affiliations

Soon will be listed here.

Abstract

Objectives: The relationship between elevated ferritin levels and metabolic abnormalities in PCOS patients, and whether ferritin is a cause or a consequence, is still debated. This study aimed to evaluate the impacts of the fourth generation combined oral contraceptive containing ethinyl estradiol/drospirenone (EE 30 mcg/DRSP 3 mg), known for its favorable metabolic profile and lower side effect risk, on iron metabolism in PCOS patients, while also exploring the potential relationship between metabolic parameters and iron status.

Methods: The retrospective analysis was conducted on 81 women aged 18-45, diagnosed with PCOS according to the Rotterdam criteria and treated with EE/DRSP for six months. Exclusion criteria were lack of data, secondary hyperandrogenemia, major medical conditions, or recent use of medications affecting hormone levels or iron metabolism. Pre- and post-treatment anthropometric measurements, hormonal and metabolic markers, and iron parameters were obtained from records.

Results: Post-treatment ferritin levels significantly increased (p = 0.001), while hemoglobin, hematocrit, and transferrin saturation decreased especially in overweight/obese patients (p = 0.012, p = 0.002, p = 0.017 respectively), suggesting a response to inflammation rather than iron storage disorders. Although overall CRP levels did not change significantly, post-treatment CRP levels were higher in overweight/obese patients compared to lean PCOS patients (p = 0.003). Ferritin levels were positively correlated with body mass index (p = 0.008, r = 0.310), insulin resistance indices (p = 0.027, r = 0.248), and the free androgen index (p = 0.001, r = 0.367) after treatment. Pre-treatment menstrual cycle length had no effect on ferritin.

Conclusions: The study revealed a paradoxical increase in ferritin levels with EE/DRSP treatment, highlighting the complex role of ferritin as a metabolic marker in PCOS patients, particularly in relation to obesity, which is typically associated with low-grade chronic inflammation.

References

Teede H, Tay C, Laven J, Dokras A, Moran L, Piltonen T . Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023; 189(2):G43-G64. DOI: 10.1093/ejendo/lvad096. View

Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz B . The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016; 31(12):2841-2855. DOI: 10.1093/humrep/dew218. View

Legro R, Arslanian S, Ehrmann D, Hoeger K, Murad M, Pasquali R . Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12):4565-92. PMC: 5399492. DOI: 10.1210/jc.2013-2350. View

Cooney L, Dokras A . Cardiometabolic Risk in Polycystic Ovary Syndrome: Current Guidelines. Endocrinol Metab Clin North Am. 2021; 50(1):83-95. DOI: 10.1016/j.ecl.2020.11.001. View

Zhuang C, Luo X, Wang W, Sun R, Qi M, Yu J . Corrigendum: Cardiovascular risk according to body mass index in reproductive-aged women with polycystic ovary syndrome: a systematic review and meta-analysis. Front Cardiovasc Med. 2023; 10:1186990. PMC: 10317040. DOI: 10.3389/fcvm.2023.1186990. View

Ollila M, Hoek A, Piltonen T . The association between polycystic ovary syndrome and early cardiovascular disease morbidity strengthens. Eur J Endocrinol. 2023; 189(1):R4-R5. DOI: 10.1093/ejendo/lvad083. View

Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay C . Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2023; 189(1):S1-S16. DOI: 10.1093/ejendo/lvad082. View

Mathew M, Sivaprakasam S, Phy J, Bhutia Y, Ganapathy V . Polycystic ovary syndrome and iron overload: biochemical link and underlying mechanisms with potential novel therapeutic avenues. Biosci Rep. 2022; 43(1). PMC: 9867939. DOI: 10.1042/BSR20212234. View

Roemhild K, von Maltzahn F, Weiskirchen R, Knuchel R, von Stillfried S, Lammers T . Iron metabolism: pathophysiology and pharmacology. Trends Pharmacol Sci. 2021; 42(8):640-656. PMC: 7611894. DOI: 10.1016/j.tips.2021.05.001. View

10.

Montonen J, Boeing H, Steffen A, Lehmann R, Fritsche A, Joost H . Body iron stores and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetologia. 2012; 55(10):2613-2621. PMC: 3433660. DOI: 10.1007/s00125-012-2633-y. View

11.

Cook J, Flowers C, Skikne B . The quantitative assessment of body iron. Blood. 2003; 101(9):3359-64. DOI: 10.1182/blood-2002-10-3071. View

12.

Kim J, Kang K, Yoon T, Shim S, Lee W . Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome. Fertil Steril. 2014; 102(2):548-554.e2. DOI: 10.1016/j.fertnstert.2014.04.031. View

13.

Escobar-Morreale H, Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero J, Sancho J, San Millan J . Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care. 2005; 28(8):2042-4. DOI: 10.2337/diacare.28.8.2042. View

14.

Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero J, Sanchon R, San Millan J, Escobar-Morreale H . Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care. 2007; 30(9):2309-13. DOI: 10.2337/dc07-0642. View

15.

Behboudi-Gandevani S, Abtahi H, Saadat N, Tohidi M, Ramezani Tehrani F . Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial. J Ovarian Res. 2019; 12(1):78. PMC: 6716867. DOI: 10.1186/s13048-019-0554-9. View

16.

Luque-Ramirez M, Ortiz-Flores A, Martinez-Garcia M, Insenser M, Quintero-Tobar A, de Lope Quinones S . Effect of Iron Depletion by Bloodletting vs. Observation on Oxidative Stress Biomarkers of Women with Functional Hyperandrogenism Taking a Combined Oral Contraceptive: A Randomized Clinical Trial. J Clin Med. 2022; 11(13). PMC: 9267723. DOI: 10.3390/jcm11133864. View

17.

Yang J, Chou C, Yang W, Ho H, Yang Y, Chen M . Iron stores and obesity are negatively associated with ovarian volume and anti-Müllerian hormone levels in women with polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2015; 54(6):686-92. DOI: 10.1016/j.tjog.2014.11.025. View

18.

Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B . Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology. 2006; 131(3):788-96. DOI: 10.1053/j.gastro.2006.07.007. View

19.

Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen B . IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9):1271-6. PMC: 398432. DOI: 10.1172/JCI20945. View

20.

Tussing-Humphreys L, Nemeth E, Fantuzzi G, Freels S, Guzman G, Holterman A . Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity (Silver Spring). 2009; 18(7):1449-56. DOI: 10.1038/oby.2009.319. View